CRO oversight

New non-compromise early-phase progression accelerator launched

26 May 2026

Carbogen AMCIS introduces Sprint for early-phase development, a new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour. Sprint has been designed to...

- Advertisement -

- Advertisement -

- Advertisement -

- Advertisement -

Latest posts

Phase 1-2

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

Funding & Finance

US$ 8.5 million investment in malaria and other R&D projects planned among pharma giants

Phase 1-2

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

CRO oversight

New non-compromise early-phase progression accelerator launched

Phase 3

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

CRO oversight

New non-compromise early-phase progression accelerator launched

Latest posts

Inhibrx provides clinical update on ozekibart in late line colorectal cancer

US$ 8.5 million investment in malaria and other R&D projects planned among pharma giants

Positive phase 1 data for RAG-17 in amyotrophic lateral sclerosis patients with mutations in the superoxide dismutase 1 gene

New non-compromise early-phase progression accelerator launched

AstraZeneca to seek accelerated approval of Ultomirisin in immunoglobulin A nephropathy on phase 3 data

Menu